Abstract Number: 742 • 2017 ACR/ARHP Annual Meeting
Quantitative CT Evalutation in Diffuse Interstitial Lung Involvement in Systemic Sclerosis: Usefulness of Lung Texture Analysis to Predict the Functional Change over Time
Background/Purpose: The prognosis of patients with scleroderma and interstitial lung involvement (SSc-ILD) can be evaluated by combining data of pulmonary function tests (PFTs) and high-resolution…Abstract Number: 743 • 2017 ACR/ARHP Annual Meeting
Impact of Detect on Right Heart Catheterization Referral and Results; Data from a Prospective, Unselected, Systemic Sclerosis Cohort
Background/Purpose: The DETECT calculator has been freely available as a tool for earlier detection and diagnosis of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)…Abstract Number: 744 • 2017 ACR/ARHP Annual Meeting
Prediction of All-Cause Mortality and Pulmonary Arterial Hypertension (PAH) Progression in Systemic Sclerosis (SSc), an Echocardiography Study
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of death in systemic sclerosis (SSc). Annual echocardiograms (echo) are recommended to detect PAH…Abstract Number: 745 • 2017 ACR/ARHP Annual Meeting
An International Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis
Background/Purpose: Raynaud’s phenomenon (RP) is consistently ranked highest in patient surveys exploring the frequency and impact of disease related manifestations of systemic sclerosis (SSc). SSc-RP…Abstract Number: 746 • 2017 ACR/ARHP Annual Meeting
Comparison of Disease Characteristics in Patients with Juvenile-Onset and Adult-Onset Progressive Systemic Sclerosis
Background/Purpose: Progressive systemic sclerosis (PSSc) has been known to affect mainly adults of 30-50 years of age. Juvenile –onset has been reported to be rare…Abstract Number: 747 • 2017 ACR/ARHP Annual Meeting
Autoantibodies to Rpp25 (Th/To) Are Specific Markers for Systemic Sclerosis and Are Associated with Limited Cutaneous Disease and Young Age at Disease Onset
Autoantibodies to Rpp25 (Th/To) are specific markers for systemic sclerosis and are associated with limited cutaneous disease and young age at disease onset[MM1] Boyang Zheng4, Martial…Abstract Number: 748 • 2017 ACR/ARHP Annual Meeting
Scleromyxedema Phenotype Pre- and Post-Treatment with Intravenous Immunoglobulin
Background/Purpose: Scleromyxedema is a rare scleroderma mimic that often responds to intravenous immunoglobulin therapy (IVIG). The clinical and biochemical changes in response to treatment have…Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…Abstract Number: 750 • 2017 ACR/ARHP Annual Meeting
Diltiazem Gel As a New Local Treatment for Scleroderma Digital Ulcers
Background/Purpose: Assessing the effect of Diltiazem gel on healing process of scleroderma digital ulcers and comparing its effect with Nitroglycerin ointment and placebo. Methods: Ninety…Abstract Number: 751 • 2017 ACR/ARHP Annual Meeting
Effect of Probiotics on the Gastrointestinal Symptoms and Immune Parameters in Patients with Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Background/Purpose: Abnormalities in the intestinal microbiota have been associated with several autoimmune diseases, including systemic sclerosis (SSc). Recent studies have demonstrated the potential of probiotics…Abstract Number: 752 • 2017 ACR/ARHP Annual Meeting
Role of the Six-Minute Walk Test in Systemic Sclerosis: Five Years Evolution
TitleRole of the Six-Minute Walk Test in Systemic Sclerosis: five years evolution. Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading…Abstract Number: 753 • 2017 ACR/ARHP Annual Meeting
The Histone Demethylase Jumonji Domain-Containing Protein 3 (JMJD3) As Central Mediator of Fibroblast Activation
Background/Purpose: Epigenetic modifications are key drivers of chronic fibroblast activation. Trimethylation of histone 3 at lysine residue K27 (H3K27me3) is a repressive modification, that is…Abstract Number: 754 • 2017 ACR/ARHP Annual Meeting
Interferon Siganture in Systemic Sclerosis Lung Microvascular Endothelial Cells
Background/Purpose: Systemic Sclerosis (SSc) is characterized by severe fibroproliferative vasculopathy, exaggerated deposition of extracellular matrix molecules (ECM) in skin and multiple internal organs, and alterations…Abstract Number: 755 • 2017 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Pattern in Systemic Sclerosis Microvascular Endothelial Cells: Identification of Epigenetically Affected Key Genes and Pathways
Background/Purpose: The etiology of systemic sclerosis (SSc) is not clear, but there is evidence suggesting a critical role for epigenetic alterations in disease pathogenesis and…Abstract Number: 756 • 2017 ACR/ARHP Annual Meeting
Novel Machine Learning Classifier Accurately Predicts Intrinsic Molecular Subsets for Patients with Systemic Sclerosis
Background/Purpose: High-throughput gene expression profiling of skin biopsies from patients with systemic sclerosis (SSc) has identified four “intrinsic” gene expression subsets conserved across multiple cohorts…
ACR Meeting Abstracts